Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin ® (bevacizumab)

First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee THOUSAND OAKS, Calif., July 13, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). ABP 215 is a biosimilar candidate to Avastin® (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA. "Amgen has worked diligently to apply our more than 35 years of experience in biotechnology to the development of biosimilars," said Sean E...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news